Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA

The latest drug development news and highlights from our FDA Performance Tracker.  

Keeping Track Feature image

It's hard to keep the US regulatory and approval news brief this week: The Center for Drug Evaluation and Research’s novel agent approvals count for 2018 reached 41 with the approval of three new oncologics – Regeneron Pharmaceuticals Inc. and Sanofi’s Libtayo (cemiplimab-rwlc), Pfizer Inc.’s Vizimpro (dacomitinib) and Verastem Inc.’s Copiktra (duvelisib) – as well as Eli Lilly & Co.’s migraine preventative Emgality (galcanezumab-gnlm).

The agency also closed out the week with its first approval under the Limited Population Pathway for antibacterial and antifungal...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet